HC Wainwright Predicts PepGen’s Q1 Earnings (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for PepGen in a note issued to investors on Monday, February 24th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.75) per share for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.74) EPS.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.13.

PEPG has been the subject of several other research reports. Wedbush dropped their price objective on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Bank of America cut shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research report on Monday, December 16th.

PepGen Stock Performance

PEPG opened at $1.71 on Wednesday. The company has a market cap of $55.75 million, a PE ratio of -0.57 and a beta of 1.53. PepGen has a 1 year low of $1.16 and a 1 year high of $19.30. The firm has a 50 day moving average price of $2.46 and a 200 day moving average price of $5.78.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PEPG. China Universal Asset Management Co. Ltd. acquired a new stake in PepGen during the 4th quarter valued at $26,000. Corton Capital Inc. acquired a new position in PepGen in the 4th quarter worth $68,000. Allspring Global Investments Holdings LLC purchased a new position in PepGen in the 3rd quarter valued at about $95,000. XTX Topco Ltd acquired a new stake in shares of PepGen during the third quarter valued at about $130,000. Finally, Deutsche Bank AG grew its stake in shares of PepGen by 442.5% during the fourth quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock valued at $170,000 after acquiring an additional 36,489 shares in the last quarter. 58.01% of the stock is owned by institutional investors and hedge funds.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.